Indication
As monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
Medicine details
- Medicine name:
- cemiplimab (Libtayo)
- SMC ID:
- SMC2719
- Pharmaceutical company
- Regeneron Pharmaceuticals Inc
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 10 February 2025
- SMC meeting date:
- 07 January 2025
- Patient group submission deadline:
- 04 November 2024